GLS-5310 Drug Asset Due Diligence Report 2026

This GLS-5310 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

181

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether GLS-5310 can convert its DNA vaccine, Prophylactic vaccine profile and SARS-CoV-2 S protein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	GLS-5310 (query alias: GLS-5310)
Modality / target	DNA vaccine, Prophylactic vaccine; SARS-CoV-2 S protein; SARS-CoV-2 S protein inhibitors
Highest global status	Phase 2
Originator	GeneOne Life Science, Inc.
Active developers	Korea University Guro Hospital

The MCP disease footprint includes COVID-19. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05182567	Phase 1	Unknown status	69	Primary endpoint not disclosed in English source
NCT05085639	Phase 1	Unknown status	30	Primary endpoint not disclosed in English source
NCT04673149	Phase 1/2	Completed	171	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults

Phase 1/2; n=171; evaluation: Not stated in English source. Reported fields: Number of Serious Adverse Events = 0 serious adverse events ; Number of Serious Adverse Events = 0 serious adverse events

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

GLS-5310 addresses COVID-19. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—DNA vaccine, Prophylactic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 181 matched transaction record(s) under the scope “target-level comparable: SARS-CoV-2 S protein.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: SARS-CoV-2 S protein records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-08-06	Arcturus and CSL Seqirus have concluded their sa-mRNA collaboration through a termination and settlement agreement following a joint review of the partnership.	Approved	US$200.0M upfront; US$4,300.0M milestones; US$4,500.0M stated total
2026-02-11	Moderna transfer its Covid-19 vaccine technology to Mexican pharma company Liomont.	Approved	Financial terms not disclosed
2026-01-21	Karolinska Development’s portfolio company Dilafor signs binding term sheet with Exeltis for a license agreement regarding tafoxiparin	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Immunogenicity durability and clinically meaningful protection
Population selection, endpoint timing, and comparator relevance
Manufacturing consistency, distribution, and uptake

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO